Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Netflix Inc NFLX

Alternate Symbol(s):  N.NFLX

Netflix, Inc. is a provider of entertainment services. The Company acquires, licenses and produces content, including original programming. The Company provides paid memberships in approximately 190 countries offering television (TV) series, films and games across a wide variety of genres and languages. Its members can play, pause and resume watching as much as they want, anytime, anywhere, and can change their plans at any time. The Company offers members the ability to receive streaming content through a host of Internet-connected devices, including TVs, digital video players, TV set-top boxes and mobile devices. The Company also has agreements with various cable, satellite and telecommunications operators to make its service available through TV set-top boxes. The Company's paid plans range from the United States dollar equivalent of $1 to $28 per month, and pricing on its extra member sub accounts range from the United States dollar equivalent of $2 to $8 per month.


NDAQ:NFLX - Post by User

<< Previous
Bullboard Posts
Next >>
Post by MandyMooreon Jun 03, 2022 3:47am
96 Views
Post# 34728650

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance


FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets clearance
 
FSD Pharma Inc CEO Anthony Durkacz told Proactive that the company is ready to proceed with the planned Phase 2 clinical trial of its FSD-201 drug candidate as soon as it gets the go-ahead from the US Food and Drug Administration and Health Canada. That's after submitting Investigational New Drug (IND) applications to the two bodies this week. Armed with cash of about $50 million following the $16.4 million disposal of its former cannabis production facility in Ontario, Durkacz said FSD is also moving full-steam ahead on its two other drug candidates and may look for other opportunities. A special dividend may also be on the cards, he added.


 
<< Previous
Bullboard Posts
Next >>